WASHINGTON, April 23 (Reuters) – The White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Regeneron is the sole drugmaker among 17 large pharmaceutical companies that received letters from President Donald Trump in July that was left to sign such an agreement.
The company did not immediately respond to Reuters’ request for comment.
Shares of the company were up more than 2% in morning trading.
(Reporting by Trevor Hunnicutt, Sriparna Roy in Bengaluru; Writing by Ryan Patrick Jones; Editing by Susan Heavey)